For research use only. Not for therapeutic Use.
Sunitinib Free Base（Cat No.:A000114）is a multi-targeted tyrosine kinase inhibitor that blocks several receptors, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit. It is primarily used in the treatment of advanced renal cell carcinoma, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors. By inhibiting these key receptors, sunitinib disrupts tumor growth, angiogenesis, and metastasis, making it an effective anticancer agent. Its broad spectrum of activity against multiple signaling pathways has established sunitinib as a crucial therapeutic option for managing various solid tumors.
| Catalog Number | A000114 |
| CAS Number | 557795-19-4 |
| Synonyms | U11248 |
| Molecular Formula | C22H27FN4O2 |
| Purity | ≥95% |
| Target | PDGFR |
| Solubility | >19.9mg/mL in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| InChI | InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- |
| InChIKey | WINHZLLDWRZWRT-ATVHPVEESA-N |
| SMILES | CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C |
| Reference | 1: Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib 2: MacIntyre J. Pharmacologic application of sunitinib malate in the management 3: Reddy K. Phase III study of sunitinib malate (SU11248) versus interferon-alpha 4: Cabebe E, Wakelee H. Sunitinib: a newly approved small-molecule inhibitor of |
